Patient (pt) reported pain and health-related quality of life (HRQoL) by genomic loss of heterozygosity (gLOH) status in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1

Authors :: F. Saad
A. Stenzl
N. Mehra
A. Stirling
V. Renard
J-P. Machiels
T. Dorff
M. Maruzzo
J. Nazari
H. Bhattacharyya
C. Healy
A. Niyazov
K. Fizazi
Source :: European Urology Open Science. 45:S172-S174
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools